![Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - Diabetes Research and Clinical Practice Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - Diabetes Research and Clinical Practice](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2053791383/2060350355/gr1.jpg)
Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - Diabetes Research and Clinical Practice
![Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily - Journal Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily - Journal](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ca92e379-083a-4e47-849d-8d99eec04f75/gr1.jpg)
Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily - Journal
![Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study - Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2012320312/2034333992/gr1.jpg)
Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study -
![Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study | BMC Pulmonary Medicine | Full Text Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study | BMC Pulmonary Medicine | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2466-14-2/MediaObjects/12890_2012_Article_650_Fig3_HTML.jpg)
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study | BMC Pulmonary Medicine | Full Text
![Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results](https://www.natap.org/2016/images/072916/072916-3/IAC1.gif)
Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results
Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021
![Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials - Radiotherapy and Oncology Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials - Radiotherapy and Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d87e56a5-1c6e-4385-aba8-b21849591cca/gr1.jpg)
Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials - Radiotherapy and Oncology
![Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram](https://www.researchgate.net/publication/325372028/figure/fig1/AS:630331015172096@1527294033000/Patient-flow-diagram-BID-twice-daily-PK-pharmacokinetics-QD-once-daily.png)
Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram
PLOS ONE: Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach
![Abbreviations: BID = twice daily; d = days; IV = intravenous; QID = 4... | Download Scientific Diagram Abbreviations: BID = twice daily; d = days; IV = intravenous; QID = 4... | Download Scientific Diagram](https://www.researchgate.net/profile/Myron-Genel/publication/309744625/figure/fig2/AS:624439670616068@1525889427306/Abbreviations-BID-twice-daily-d-days-IV-intravenous-QID-4-times-per-day-SCFN.png)
Abbreviations: BID = twice daily; d = days; IV = intravenous; QID = 4... | Download Scientific Diagram
![Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation - Journal of the American Pharmacists Association Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation - Journal of the American Pharmacists Association](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fd7317d4-a966-400d-a8c2-4baebd7b1ff2/gr1.jpg)
Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation - Journal of the American Pharmacists Association
![A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors | Scientific Reports A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-82671-w/MediaObjects/41598_2021_82671_Fig1_HTML.png)